{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:35:00Z","timestamp":1790681700632,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/bjc.2017.160","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T20:01:46Z","timestamp":1497988906000},"page":"189-194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment"],"prefix":"10.1038","volume":"117","author":[{"given":"Richard","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Gabriela","family":"Chiorean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio Max S","family":"Rocha-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Portnoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"BFbjc2017160_CR1","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/jso.21374","volume":"100","author":"J Albores-Saavedra","year":"2009","unstructured":"Albores-Saavedra J, Schwartz AM, Batich K, Henson DE (2009) Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol 100: 598\u2013605.","journal-title":"J Surg Oncol"},{"key":"BFbjc2017160_CR2","doi-asserted-by":"publisher","first-page":"S322","DOI":"10.1097\/00005344-199526003-00097","volume":"26","author":"DP Brooks","year":"1995","unstructured":"Brooks DP, DePalma PD, Pullen M, Gellai M, Nambi P (1995) Identification and function of putative ETB receptor subtypes in the dog kidney. J Cardiovasc Pharmacol 26: S322\u2013S325.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFbjc2017160_CR3","unstructured":"The Christie NHS Foundation Trust. Active symptom control alone or with mFOLFOX chemotherapy for locally advanced\/metastatic biliary tract cancers (ABC06). NCT01926236. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01926236 (accessed on 10 April 2017)."},{"issue":"11","key":"BFbjc2017160_CR4","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1002\/cncr.30571","volume":"123","author":"L Goyal","year":"2017","unstructured":"Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX (2017) A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 123 (11): 1979\u20131988.","journal-title":"Cancer"},{"key":"BFbjc2017160_CR5","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.3748\/wjg.v21.i7.2096","volume":"21","author":"JF Guion-Dussere","year":"2015","unstructured":"Guion-Dussere JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F (2015) FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 21: 2096\u20132101.","journal-title":"World J Gastroenterol"},{"key":"BFbjc2017160_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1179\/1973947813Y.0000000133","volume":"26","author":"S He","year":"2014","unstructured":"He S, Shen J, Sun X, Liu L, Dong J (2014) A phase II FOLFOX-4 regimen as second-line treatment advanced biliary tract cancer refractory to gemcitabine\/cisplatin. J Chemother 26: 243\u2013247.","journal-title":"J Chemother"},{"key":"BFbjc2017160_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/09553009114551621","volume":"60","author":"RK Jain","year":"1991","unstructured":"Jain RK (1991) Haemodynamic and transport barriers to the treatment of solid tumours. Int J Radiat Biol 60: 85\u2013100.","journal-title":"Int J Radiat Biol"},{"key":"BFbjc2017160_CR8","doi-asserted-by":"crossref","first-page":"e14688","DOI":"10.1200\/jco.2012.30.15_suppl.e14688","volume":"30","author":"SC Lee","year":"2012","unstructured":"Lee SC, Kim K, Kim H, Kim HJ, Kim SH, Bae S-B, Kim CK, Lee N, Lee KT, Park SK, Won J-H, Yun J, Hong DS, Park HS (2012) Prognostic factor analysis of second-line chemotherapy in advanced biliary tract cancer. J Clin Oncol 30, Abstract e14688.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017160_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc990","volume":"3","author":"J Nelson","year":"2003","unstructured":"Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110\u2013116.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2017160_CR10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s10637-010-9417-3","volume":"29","author":"SY Oh","year":"2011","unstructured":"Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, Lee GW, Hwang IG, Jang JS, Kwon HC, Kang JH (2011) Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 29: 1066\u20131072.","journal-title":"Invest New Drugs"},{"key":"BFbjc2017160_CR11","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0959-8049(01)00214-3","volume":"37","author":"P Papakostas","year":"2001","unstructured":"Papakostas P, Kouroussis C, Androulakis N, Samelis G, Aravantinos G, Kalbakis K, Sarra E, Souglakos J, Kakolyris S, Georgoulias V (2001) First-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicenter phase II study. Eur J Cancer 37: 1833\u20131838.","journal-title":"Eur J Cancer"},{"key":"BFbjc2017160_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/00000421-199902000-00019","volume":"22","author":"R Pazdur","year":"1999","unstructured":"Pazdur R, Royce ME, Rodriguez GI, Rinaldi DA, Patt YZ, Hoff PM, Burris HA (1999) Phase II trial of docetaxel for cholangiocarcinoma. Am J Clin Oncol 22: 78\u201381.","journal-title":"Am J Clin Oncol"},{"key":"BFbjc2017160_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1211\/0022357056488","volume":"57","author":"A Rai","year":"2005","unstructured":"Rai A, Rajeshkumar NV, Shord S, Gulati A (2005) ET-B receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. J Pharm Pharmacol 57: 869\u2013876.","journal-title":"J Pharm Pharmacol"},{"key":"BFbjc2017160_CR14","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/pros.20556","volume":"67","author":"NV Rajeshkumar","year":"2007","unstructured":"Rajeshkumar NV, Matwyshyn G, Gulati A (2007) IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. Prostate 67: 701\u2013713.","journal-title":"Prostate"},{"key":"BFbjc2017160_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-005-9000-3","volume":"94","author":"NV Rajeshkumar","year":"2005","unstructured":"Rajeshkumar NV, Rai A, Gulati A (2005) Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 94: 237\u2013247.","journal-title":"Breast Cancer Res Treat"},{"key":"BFbjc2017160_CR16","first-page":"408","volume":"5","author":"JE Rogers","year":"2014","unstructured":"Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT (2014) Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol 5: 408\u2013413.","journal-title":"J Gastrointest Oncol"},{"key":"BFbjc2017160_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","volume":"30","author":"T Sasaki","year":"2012","unstructured":"Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K (2012) Multicenter phase Ii study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory gemcitabine. Invest New Drugs 30: 708\u2013713.","journal-title":"Invest New Drugs"},{"key":"BFbjc2017160_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66: 7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"BFbjc2017160_CR19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00280-013-2106-0","volume":"71","author":"E Suzuki","year":"2013","unstructured":"Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, Boku N, Yanagimoto H, Sato T, Furuse J (2013) A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71: 1141\u20131146.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc2017160_CR20","volume-title":"The Twelfth International Conference on Endothelin","author":"AG Tolcher","year":"2011","unstructured":"Tolcher AG, Gari V, Reddy G, Lenaz L, Tidmarsh G, Gulati A (2011) A phase I, open label, ascending dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the endothelin B agonist, SPI-1620, in patients with recurrent or progressive carcinoma. The Twelfth International Conference on Endothelin Vol. 9. The British Pharmacological Society: Cambridge, UK."},{"key":"BFbjc2017160_CR21","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273\u20131281.","journal-title":"N Engl J Med"},{"key":"BFbjc2017160_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ejca.2012.08.003","volume":"49","author":"T Walter","year":"2013","unstructured":"Walter T, Horgan AM, McNamara M, McKeever L, Min T, Hedley D, Serra S, Krzyzanowska MK, Chen E, Mackay H, Feld R, Moore M, Knox JJ (2013) Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a larger retrospective study. Eur J Cancer 49: 329\u2013335.","journal-title":"Eur J Cancer"},{"key":"BFbjc2017160_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihawa H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411\u2013415.","journal-title":"Nature"},{"key":"BFbjc2017160_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S1470-2045(09)70333-X","volume":"11","author":"AX Zhu","year":"2010","unstructured":"Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV (2010) Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 11: 48\u201354.","journal-title":"Lancet Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2017160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017160","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:38:03Z","timestamp":1684417083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2017160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["BFbjc2017160"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.160","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]},"assertion":[{"value":"1 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Song is an employee of Spectrum. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}